Feed OGN
OG

Organon & Co. OGN NYSE · Healthcare · United States

$13.90 -0.07% -$0.01

Summary

53 / 100 · Bulios Score

What speaks for it

  • The share price is below the Bulios Fair Price.
  • Out of every 100 USD of revenue, 11 USD is left as free cash.

What to watch

  • Earnings per share fell by 41% a year over the last 3 years.
  • Repaying its net debt would take 5.5 years of operating profit.
  • It cut its dividend by 70% last year.
  • Out of every 100 USD of revenue, only 3.5 USD is left as net profit.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Undervalued Price today $13.9

By our assumptions the business is worth more than its shares cost today.

P/E today 17.2 172% higher
5-year average P/E 6.3
P/E today 17.2
Drug Manufacturers - General industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 17.2 USD for 1 USD of yearly profit. Over the last five years it was 6.3 USD on average.

Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue fell by 1.0% a year over 5 years. Over the last 3 years it grew by 0.2% a year. Earnings per share fell by 41% a year over the last 3 years.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Drug Manufacturers - General) 14 USD

Out of every 100 USD of revenue, 3.5 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Debt is a burden

Repaying all its debt would take 12.7 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

Small, safe
Yield
0.58%
Paid out of profit
9.9%

You receive $0.08 per share a year. The company covers the payout with ease.

Dividends in detail

What do analysts expect?

Neutral

Today's price within the analysts' price targets

The average target of $11 is 21% below today's price. 22% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

The company reports no revenue by product.

By region

Non-US brings in 43% of revenue. UNITED STATES grew fastest, by 4.2% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy